Top Medical News

Larotrectinib Holds Ground as Effective Treatment in NTRK-Positive Lung Cancer

August 14th 2022

Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.

Amivantamab/Lazertinib/Chemo Regimen Gains Traction in EGFR-Mutant NSCLC

August 13th 2022

Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.

Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

August 12th 2022

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

August 12th 2022

The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction.

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

August 11th 2022

The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity.

Most Recent